A strong scientific case, based on extensive research, has been built around the potential benefits of Modufolin®. Below is a selection of available results:

  • Gustavsson, Bengt, et al. “A review of the evolution of systemic chemotherapy in the management of colorectal cancer.” Clinical colorectal cancer 14.1 (2015): 1-10. Link
  • Danenberg, Peter V., et al. “Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action.” Critical Reviews in Oncology/Hematology 106 (2016): 118-131. Link
  • Taflin, Helena, et al. “Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages.” Cancer chemotherapy and pharmacology 74.6 (2014): 1167-1174. Link
  • Correlation of tissue levels and gene expression. An analysis of the same patients – To be published, request manuscript.
  • Correlation of expression levels of folate relevant genes and prognosis in patients with CRC Stage III, adjuvant treatment with leucovorin plus at least 5-FU. Request data.
  • Odin, Elisabeth, et al. “Expression of folate pathway genes in stage III colorectal cancer correlates with recurrence status following adjuvant bolus 5-FU-based chemotherapy.” Molecular Medicine 21.1 (2015): 597. Link
  • Study 2 – Validating and confirming the importance of the hypothesis – To be published, request manuscript.
  • Stage IV, palliative treatment – request initial results.